Laurus Labs Limited delivered a robust financial performance in the first quarter of FY27, reporting a 29% year-on-year revenue increase to ₹2,026 crore and a 126% jump in net profit to ₹368 crore. The strong results were primarily driven by a 67% surge in Contract Development and Manufacturing Organization (CDMO) revenues, which reached ₹870 crore, offsetting modest growth in the Affordable Medicines segment. This top-line expansion translated into significant bottom-line gains, with earnings per share (EPS) rising 127% to ₹6.8 from ₹3.0 in the corresponding period last year.

The filing, submitted to the Bombay Stock Exchange and National Stock Exchange on July 24, 2026, highlights an EBITDA increase of 66% to ₹644 crore, representing an expanded margin of 31.8%, up from 24.8% in Q1FY26. Gross margins also widened by 330 basis points to 62.7%. Management attributed these improvements to enhanced CDMO revenue contributions, better divisional mix, and improved capacity utilization. The company maintained its aggressive investment trajectory, with capital expenditure standing at ₹394 crore, or 19% of sales, focused heavily on API/CDMO capabilities and advanced biologics infrastructure.

Financial Performance Highlights

Segmental Breakdown

The CDMO segment emerged as the primary growth engine, with small molecules revenue soaring 69% to ₹835 crore, driven by steady progression of late-stage clinical projects and commercial API supplies. The Bio segment achieved 21% year-on-year growth to ₹35 crore. In contrast, the Affordable Medicines segment recorded total revenue of ₹1,156 crore, up 10% year-on-year. Within this segment, Finished Dosage Forms (FDF) revenue grew 22% to ₹502 crore, while API revenue remained relatively flat at ₹654 crore.

What the Numbers Show

A critical observation from the Q1FY27 results is the structural shift in Laurus Labs’ revenue composition. The CDMO segment now accounts for 43% of total revenue (combining small molecules and bio), compared to approximately 33% in the prior year. This diversification is reducing reliance on the cyclical Affordable Medicines business. Furthermore, the simultaneous expansion in both gross margins (to 62.7%) and operating margins (to 31.8%) indicates that the higher-margin CDMO mix is not only driving volume but also significantly enhancing profitability efficiency. Total R&D investments, including capex R&D, rose 74% year-on-year to ₹118 crore (5.8% of revenue), reflecting heavy development efforts toward building Advanced Biologics infrastructure for Gene Therapy and Antibody Drug Conjugates (ADCs).

Strategic Initiatives and Capex

Laurus Labs continues to invest in high-growth areas, with over 85% of its capex directed toward growth projects. Key initiatives include expanding fermentation manufacturing capacity in Vizag, expected to be commissioned by Q3FY27, and advancing commercial-scale peptide production. In advanced biologics, the company in-licensed two ADC assets from Aarvik Therapeutics and is building a manufacturing facility for gene therapy and ADCs, with qualification expected by end-2027. Additionally, the second GMP production facility for cell therapy in Navi Mumbai became operational in March 2026, boosting treatment capacity to over 2,500 units.

The company also reaffirmed its environmental, social, and governance (ESG) commitments, having received Science Based Targets initiative (SBTi) validation for its near-term greenhouse gas reduction targets. These include a 42% absolute reduction in Scope 1 and 2 emissions by FY31 and a 51.6% intensity reduction in Scope 3 emissions. With a net leverage ratio stable at 1.3x and a healthy order book, Laurus Labs appears well-positioned to sustain its growth momentum through FY27.

Laurus Labs has notified the Bombay Stock Exchange and the National Stock Exchange of India Ltd. regarding a change in its directorate. The company’s Board of Directors, during a meeting held on July 24, 2026, took note of the retirement of Dr. Rajesh Koshy Chandy (DIN: 07575240) as an Independent Director. The retirement is effective from close of business hours on July 26, 2026, marking the conclusion of his second term in office, which spanned from July 27, 2021, to July 26, 2026.

The intimation was issued under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure aligns with the requirements set forth in SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026. G. Venkateswar Reddy, Company Secretary & Compliance Officer, signed the communication, confirming the procedural compliance with regulatory mandates.

Key Details of Director Change

The Board meeting commenced at 02.00 p.m. IST and concluded at 02.42 p.m. IST on July 24, 2026. The filing serves as a formal record of the cessation of Dr. Chandy’s tenure, ensuring transparency for shareholders and regulators regarding the composition of the Board.

Regulatory Compliance

The announcement was made pursuant to the mandatory disclosure norms for listed entities in India. By referencing the specific SEBI Master Circular, Laurus Labs confirmed that all requisite details regarding the reason for change, date of cessation, and term details were annexed to the filing. No new appointment was disclosed in this communication; the focus remains solely on the retirement of the outgoing director.